We don’t have to be a year behind

Kathy Redmond

Late last year, US patients with advanced renal cell cancer gained access to an oral multi-kinase inhibitor, Nexavar (sorafinib) – the first new drug approved for this disease in the last 10 years. Manufacturer Bayer had filed an application for approval with the European Medicines Agency (EMEA) around the same time as its application to the US Food and Drug Administration (FDA). However, the company states that, pending a favourable review, it does not expect the agent to become available to patients in Europe until late 2006 – nearly one year later than in the US.

Download full article

Be the first to comment

Leave a Reply

Your email address will not be published.


*


UA-77507851-1